News

Researchers have identified a new type of Charcot-Marie-Tooth disease (CMT): Recessive Intermediate CMT E, or CMTRIE. This rare subtype is caused by mutations in both copies of a gene called KCTD11. CMTRIE joins a small but growing group of intermediate CMT ...

With support of $225,483 from CMTA’s Strategy To Accelerate Research (CMTA-STAR), scientists at the University of Miami have completed an encouraging study on a potential therapy for CMT2E, an axonal CMT subtype caused by mutations in the NEFL gene. The ...

With CMTA support of $448,748, researchers are making significant progress in the development of gene editing therapies for CMT1A and CMT1B, the two most common types of demyelinating Charcot-Marie-Tooth disease (CMT). This work is part of a global research collaboration ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is excited to announce the designation of Sarah Breevoort, MD, PhD, at the Medical University of South Carolina (MUSC) in Charleston, SC, as its newest CMTA ...

By Katherine Forsey, PhD | CMTA Chief Research Officer Current treatments for Charcot-Marie-Tooth disease (CMT) focus mainly on managing symptoms. But new advances in genetic therapies are changing the conversation and offering real hope for the future. CMTA is investing heavily ...